Atrial fibrillation: Outpatient presentation and management

Circulation

Volumn 124, Issue 1, 2011, Pages 95-99

  Ezekowitz, Michael D ^a   Aikens, Timothy H ^a   Nagarakanti, Rangadham ^b   Shapiro, Timothy ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATININE; DABIGATRAN; DIGITALIS; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; EDOXABAN; FLECAINIDE; IBUTILIDE; LISINOPRIL; METFORMIN; PROCAINAMIDE; PROPAFENONE; RIVAROXABAN; SOTALOL; VERAPAMIL; WARFARIN; XIMELAGATRAN;

AGED; ANTICHOLINERGIC SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY LESION; ARTICLE; ATRIOVENTRICULAR BLOCK; BRAIN HEMORRHAGE; CARDIOVERSION; CASE REPORT; CLINICAL FEATURE; CREATININE CLEARANCE; DEPRESSION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXERCISE; EYE TOXICITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; LIVER TOXICITY; LUNG TOXICITY; LUPUS LIKE SYNDROME; MALE; MORTALITY; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINUS RHYTHM; STROKE; SYSTOLIC HEART MURMUR; THROMBOEMBOLISM; THYROID DISEASE;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; MALE; OUTPATIENTS; STROKE; TREATMENT OUTCOME;

EID: 79960379700     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.967455     Document Type: Article

References (31)

1. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, for the RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-1373.
2. Hohnloser SH, Kuck KH, Lilienthal J for the PIAF Investigators. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-1794.
3. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. (Pubitemid 35417773)
4. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347:1834-1840. (Pubitemid 35417774)
5. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U for the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696. (Pubitemid 36584236)
6. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P, for the Investigators of the Polish HOT CAFE Trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest. 2004;126:476-486. (Pubitemid 39093433)
7. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677. (Pubitemid 351860859)
8. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Alessie MA. Atrial fibrillation begets atrial fibrillation. Circulation. 1995;92:1954-1968.
9. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD, for the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
10. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131-136.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from 5 randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-2870. (Pubitemid 32537350)
13. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369-2429.
14. Albers GW, Diener HC, Grind M, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A, Frison L, Nevinson M, Partridge S; Executive Steering Committee on Behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698. (Pubitemid 37468318)
15. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximela-gatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA. 2005;293:690-698. (Pubitemid 40220342)
16. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-810.
17. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151.
18. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S, RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-2253.
19. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120:1029-1035
20. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban: Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340.e1-347.e1.
21. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators. Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159: 331-339.
22. Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ. Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159:348.e1-353.e1.
23. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
24. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNtico-aGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-641.
25. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.
26. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433-1441.
27. Ruiz-Nodar JM, Maŕin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdés M, Lip GY. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818-825. (Pubitemid 351255616)
28. Manzano-Fernández S, Pastor FJ, Maŕin F, Cambronero F, Caro C, Pascual-Figal DA, Garrido IP, Pinar E, Valdés M, Lip GY. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008;134:559-567.
29. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, Airaksinen TJ, Niemelä M, Vahlberg T, Airaksinen KE. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726-732. (Pubitemid 46439228)
30. DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, Lam L, McGowan C, Lee G, DeCaro M, Ruggiero N, Singhal S, Greenspon A. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy. 2007;27:691-696. (Pubitemid 46700961)
31. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, Wong SC, Hong MK. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18:162-164. (Pubitemid 44576090)